Bell Watching: Low Float (COEP) Has Multiple Analyst Targets Providing Suggestive Upside Potential

That's a big number. But do you know what it stands for? Bell Watching: Low Float (COEP) Has Multiple Analyst Targets Providing Suggestive Upside Potential February 29th Dear Reader, $393.61Bn... That's a big number. But do you know what it stands for? With the global cancer therapeutics market set to skyrocket to a level of nearly $400Bn according to [Precedence Research]( there could be significant room for disruption in the Biopharma arena. And one little-known company has been on the warpath working to create a platform and pipeline of innovative therapies which could generalize the treatment of many incapacitating diseases. This new Nasdaq biopharma breakout idea has a relatively [low float]( of approx. 18Mn shares which means a potential catalyst, like positive company news, could create a volatile situation in moments. When it comes to the potential for positive developments, this company may be stacked as it is currently advancing 6 potential game-changing programs on its must-see pipeline. Furthermore, analysts have signaled with their targets that this hidden gem may have wild upside potential from current levels. From Wednesday's open, [3 separate targets]( suggested over the past year indicated potential upsides of over 500%, over 700%, and over 1,900%! And if you missed it, my most recent alert to also have a strong analyst target ABSOLUTELY ERUPTED to start the week. Catapulting to a new 2024 high, my Monday morning profile opened at $.9087 and ran to a high of $1.19 for a surge of approximately 30% intraday. When you consider a pre-market high of $1.97 Monday, and a closing valuation this past Friday of $.64, there was an approximate maxed out short term move of 207% that cannot be ignored. Now, do we expect this profile to run down any price targets this week or repeat Monday's alert's moves? No. Nothing is certain. But, with this profile's chart showing it bouncing off 52-week lows recently, it may be just a matter of time until this under-the-radar Nasdaq profile starts popping up on watch-lists everywhere. Drop everything right now and pull up: *Coeptis Therapeutics Holdings, Inc. (COEP)* Coeptis Therapeutics Holdings, Inc., together with its subsidiaries including Coeptis Therapeutics, Inc. and Coeptis Pharmaceuticals, Inc., (collectively "Coeptis"), is a biopharmaceutical company developing innovative cell therapy platforms for cancer that have the potential to disrupt conventional treatment paradigms and improve patient outcomes. And right now, COEP has several potential catalysts to familiarize yourself with. Check them out: #1. A Low Float Provides The Possibility For Explosive Volatility. #2. Analysts Swoon Over COEP's Impressive Future Potential, Provide 3 Major Targets From Current Levels. #3. Strong News Monday Has Flown Beneath The Radar (Future $12Bn Autoimmune Disease Market Targeted For Disruption). #4. Could Important Chart Support Be Building For COEP After Bouncing Off Its 52-Week Low? But more on those in a second... Coeptis Therapeutics Highlights 3 Core Technologies - Universal SNAP-CAR Platform - GEAR Engineered Cell Therapy - Cord-Blood Derived Allogeneic Cell Generation Platform 2 Clinical Studies - DVX-201 for Patients with Relapsed/ Refractory AML and High Risk MDS - DVX-201 for Subjects Hospitalized for CV-19 1 Year as a Public Company - NASDAQ: COEP 5 Dev and Clinical Collaborations - University of Pittsburgh - Karolinska Institute - Fred Hutch Cancer Research Center - Duke Cancer Institute - Novant Health 13,000 Square Feet - Of Research and Development Capabilities (Through Shared Services Agreement with Deverra Therapeutics, Inc) Diverse Pipeline The Future Of Medicine Now Coeptis Therapeutics’ science is built on the notion that cell therapies should be safe, effective, and available for everyone. Recent medical breakthroughs in cell therapy are quickly leading to a renaissance in the treatment of diseases once believed to be untreatable. Coeptis is developing a proprietary, allogeneic cell generation platform and a pipeline of innovative cell therapies which we believe may universalize the treatment of many debilitating diseases. COEP's Scientific Collaboration Coeptis is collaborating with researchers from the University of Pittsburgh and contracted a prominent Clinical Research Organization (CRO) to begin developing the SNAP-CAR T cell therapy with the goal to pursue clinical trials. Coeptis has been assigned the worldwide development and commercialization rights to the licensed technology in the field of human treatment of cancer with antibody or antibody fragments using SNAP-CAR T cell technology. VyGen-Bio is a discovery-stage, cell-based immunotherapy company focused on the development of transformational technology platforms: GEAR-NK, modified natural killer cell-based therapeutics (NK cells), optimized to be co-administered with targeted antibodies; and, GEAR Diagnostic, a companion diagnostic being developed to select patient populations most likely to benefit from targeted antibody therapies. Headquartered in Tampa, Florida on the campus of the H. Lee Moffitt Cancer Center, VyGen-Bio is a majority-owned subsidiary of Vycellix, Inc. VyGen-Bio’s platforms were discovered by scientists at Karolinska Institutet (KI), Stockholm, Sweden that collaborate with VyGen-Bio. Additionally, VyGen-Bio is a member-partner in “NextGenNK”, an international Competence Center for the development of next-generation NK cell-based cancer immunotherapies based at KI and funded by Sweden’s innovations agency, Vinnova. KI is globally recognized for its Nobel Assembly, which awards the Nobel Prize in Physiology or Medicine. Grab More Here: [Company Website.]( [Company Presentation.]( ----- As mentioned above, COEP has several potential breakout catalysts to soak in right now. Here they are: #1. A Low Float Provides The Possibility For Explosive Volatility. According to the [Yahoo Finance]( website, COEP has a relatively low float. The website reports this profile to have approximately 18Mn shares in its float. Why is that important? It's important on one crucial level. Volatility. Could more positive company news in early 2024 provide a near term spark? ----- #2. Analysts Swoon Over COEP's Impressive Future Potential, Provide 3 Major Targets From Current Levels. Check out what we found over at [TipRanks]( From Wednesday's opening valuation, these 3 targets provide a significant amount of upside potential. We're talking over 500%, over 700%, and over 1,900%! With all 3 of these targets being created within the last 12 months, COEP could be viewed as undervalued from current levels. ----- #3. Strong News Monday Has Flown Beneath The Radar (Future $12Bn Autoimmune Disease Market Targeted For Disruption). The company started this week off with some big news. Check it out: Coeptis Therapeutics Adds Autoimmune Indications to Exclusive License Agreement with University of Pittsburgh for SNAP-CAR T and SNAP-CAR NK Exclusive rights to universal CAR technology platform designed to target multiple antigens simultaneously, recently expanded to include SNAP-CAR NK cells, has potential to impact various autoimmune diseases in addition to oncology indications. WEXFORD, Pa., Feb. 26, 2024 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) (the "Company" or "Coeptis"), ..., today announced that it has expanded its exclusive license agreement with the University of Pittsburgh to include autoimmune indications as part of its ongoing development of SNAP-CAR T and SNAP-CAR NK. This amended agreement builds upon the original exclusive license agreement with the University of Pittsburgh for SNAP-CAR T Cells, a "universal" CAR T technology platform designed to target multiple antigens simultaneously and potentially address a range of hematologic and solid tumors, and a recent amendment to the agreement for SNAP-CAR NK, an allogeneic natural killer (NK) cell therapy platform. ... "We remain committed to developing these remarkable technologies as treatments for various indications across oncology where there is immense unmet need, however we also recognize the enormous potential for these platform technologies to address and possibly revolutionize the treatment landscape of autoimmune diseases," said Dave Mehalick, President and CEO of Coeptis Therapeutics. "Our SNAP-CAR technologies have the potential to position us at the forefront of next-generation autoimmune directed therapies targeting multiple antigens through combinatorial use of different adaptors." ... According to the American Autoimmune Related Disease Association, there are more than 100 autoimmune diseases impacting 1 in every 5 Americans, 75% of whom are women. These diseases are among the top 10 causes of death in America, causing great pain and suffering, with significant socioeconomic impact as well. Globally, the treatment market is forecasted to grow from $7.68Bn in 2024 to $12.64Bn in 2028, according to The Business Research Company. [Read the full article here.]( ----- #4. Could Important Chart Support Be Building For COEP After Bouncing Off Its 52-Week Low? Take a look at COEP's 6-month chart below: A couple weeks back, COEP dropped down to create a 52-week low, but has since been building momentum. And as of Wednesday morning, COEP had pushed above [4 key short term technical lines]( in its: - 5-Day Simple Moving Average (SMA) - 20-Day SMA - 5-Day Exponential Moving Average (EMA) - 13-Day EMA From that 52-week low set back on February 14th, COEP has moved over 50% in the matter of 2 weeks. Could this be the start of a major move back towards previous highs? ----- COEP Recap - The Top Potential Breakout Catalysts To Know #1. A Low Float Provides The Possibility For Explosive Volatility. #2. Analysts Swoon Over COEP's Impressive Future Potential, Provide 3 Major Targets From Current Levels. #3. Strong News Monday Has Flown Beneath The Radar (Future $12Bn Autoimmune Disease Market Targeted For Disruption). #4. Could Important Chart Support Be Building For COEP After Bouncing Off Its 52-Week Low? ----- Get COEP on your radar now. Sincerely, FierceAnalyst | Jaks Swift Editorial Writer (Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.) FierceInvestor (FierceInvestor . com) is owned by SWN Media LLC, a limited liability company. Ownership of FI has now moved to a single individual. Disclosure: I am not a lic-ensed fina-ncial adviser. Make sure to always do your own research and due diligence on any day and swing profile I bring to your attention. Fierce full disclosure is to be read and fully understood before using Fierce's website, or joining Fierce's email or text list. By viewing Fierce's website and/or reading Fierce's email or text newsletter you are agreeing to -> [( An owner of SWN Media LLC owns and operates smallcapfirm . com (“SCF”), owns and operates stockwirenews . com (“SWN”), and owns and operates stockstreetwire . com ("SSW"). From time to time, SWN, SCF, FI, and/or SSW will publicly disseminate information about a company via website, email, SMS and other points of media. Pursuant to an agreement between SWN Media LLC and TD Media LLC, FierceInvestor (FI) has been hired for a period beginning on 5/30/23 and ending on 6/1/23 to publicly disseminate information about (COEP) via Website, Email and SMS. SWN Media LLC was paid fifteen thousand USD via bank wire transfer. We own zero shares of (COEP). Pursuant to an agreement between SWN Media LLC and TD Media LLC, FierceInvestor (FI) has been hired for a period beginning on 2/28/24 and ending on 2/29/24 to publicly disseminate information about (COEP) via Website, Email and SMS. SWN Media LLC was paid twenty thousand USD via bank wire transfer. We own zero shares of (COEP). To date we've now been compensated thirty-five thousand USD via bank wire transfer to disseminate information about (COEP). A member of SWN Media LLC is also a member of TD Media LLC. Pursuant to an agreement between TD Media LLC and AdVibes LLC, TD Media LLC has been hired for a period beginning on 02/28/2024 and ending on 02/29/2024 to publicly disseminate information about (COEP:US) via digital communications. We have been paid an additional fifty-six thousand dollars USD. To date we have been paid two hundred and fifty-six thousand dollars USD to disseminate information about (COEP:US) via digital communications. We own zero shares of (COEP:US). [( Fierce | 4834 NW 2nd Ave, Unit #388, Boca Raton, FL 33431 [Unsubscribe {EMAIL}]( [Update Profile]( | [Constant Contact Data Notice]( Sent by jaks@fierceanalyst.ccsend.com